- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21:26 | Genmab sheds another clinical ADC from $1.8B ProfoundBio buy | ||
| 18:26 | Repare finds fix as biotech agrees to XenoTherapeutics buyout | ||
| 17:26 | Bayer opens Beijing incubator and names initial occupants, tightening ties to China | ||
| 16:26 | J&J buys into Halda cell death tech with $3B acquisition, beefing up prostate cancer pipeline | ||
| 16:26 | Nxera lays off 15% of staff, pivots pipeline focus in profitability push | ||
| 14:26 | Nuvalent shares lung cancer data, sparking race to FDA for would-be Pfizer rival | ||
| Fr | Sensei shrinks workforce by 65%, terminates 3 executive roles | ||
| Fr | Merck pays $9.2B for Cidara, picking up flu antiviral spurned by J&J | ||
| Fr | BMS and J&J's blood thinner flunks phase 3, denting big blockbuster hopes | ||
| Fr | Analysts skeptical Applied Tx can get rare disease drug to market as FDA talks drag on | ||
| Do | Pfizer finalizes Metsera buy after contentious bidding war with Novo Nordisk | ||
| Do | Third Arc Bio pens back-loaded $840M pact for Adagene's masking T-cell engager tech | ||
| Do | Century, Candel and MacroGenics call time on certain clinical trials to conserve cash | ||
| Do | Day One pens $285M deal for Mersana and its clinical-stage B7-H4 ADC | ||
| Do | Zealand hits pause on dual GLP-1/GLP-2 asset as CMO cites 'increasingly crowded' metabolic development scene | ||
| Do | Korro lays off 34% of staff as lead drug disappoints and Novo Nordisk pauses pact | ||
| Do | Novartis' resistance-busting malaria drug GanLum hits phase 3 goal | ||
| Mi | Prasad, Makary unveil new FDA path for accelerating custom gene editing therapies | ||
| Mi | AbbVie to end Calico collab after 11-year run, plans layoffs: Stat | ||
| Mi | Leap Therapeutics jumps from bio to crypto after winding down cancer program | ||
| Mi | Alkermes races to phase 3 after posting another narcolepsy win | ||
| Mi | Bayer bails on Vividion tumor drug as part of early-stage cancer clear-out | ||
| Mi | Metagenomi sheds 25% of workforce, including CEO, to focus on preclinical hemophilia program | ||
| Di | With Summit leading the pack in PD-1xVEGF bispecifics, Pfizer lays out its own plan to replace Keytruda | ||
| Di | Neuphoria, reeling from phase 3 trial fail, mulls buyout offer from investor |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .